The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
The BD Neopak Glass Prefillable Syringe platform is designed for the complex needs of biologics and combination products
Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine
The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
Subscribe To Our Newsletter & Stay Updated
